Evaluating the antibacterial effect of a new spirooxindole derivative nanoparticle on Extended Spectrum β-Lactanases (ESBLs) producing Escherichia coli from patients with urinary tract infections at hospitals of Karaj, Iran

Due to the increase in urinary tract infection (UTI) caused by Extended- Spectrum β-lactamases (ESBLs) producing Escheria.coli strains and their resistance to conventional antibiotics, the development of new effective antimicrobial agents particularly nanoparticle based biological compounds is urgently required. The aim of this study was to evaluate the antibacterial effect of a new derivative of spirooxindole nanoparticles against ESBLs producing E. coli isolates obtained from patients with UTI.

This descriptive-observational study was performed on 60 E. coli isolates from Karaj city hospitals. Isolates were identified by standard biochemical tests. Antimicrobial susceptibility of isolates against Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, was determined using the Disk Diffusion Method. The new derivative of spiroxindole nanoparticles was prepared by electrosynthesis and examined with a scanning electron microscopy (SEM). ESBLs producing isolates were detected by the Combined Disk test. The broth microdilution method was performed to determine the Minimum inhibitory concentration (MIC) of nanoparticles

Antibiotic resistance of 60 Escherichia coli isolates was as follows: Cefepime 23.33%, Ceftazidime 16.66%, Cetfriaxone 30% and Cefotaxime 31.66%. 14 ESBLs producing Escherchia coli isolates were identified by a phenotypic confirmatory test. The MIC value of the understudied spirooxindole nanoparticles was obtained to be 50μg/ml.

Undertaking further studies, the understudied spirooxindole nanoparticle can be introduced as a new antibacterial compound.